![](/fileadmin/_processed_/csm_Neurosense-pipeline_38841e73e1.png)
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Under the agreement with Lonza AG, NeuroSense Therapeutics Ltd will advance early diagnosis and treatment in the neurodegeneration field. Last...
![](/fileadmin/Content/NewsAndStories/2024/Bildschirmfoto_2024-07-09_um_09.31.12.png)
EMA-Gate: PharmaMar wins suit against EMA
The European Commission has corrected its decision C(2018) 4831 from 2018 not to grant marketing authorisation for Aplidin (plitidepsin), a peptidic...
![](/fileadmin/_processed_/csm_quantro_747ee92cb9.png)
Quantro Therapeutics cashes in milestone payment from Boehringer Ingelheim
Austrian QUANTRO Therapeutics GmbH has reached a key milestone in its three year R&D and licence option collaboration with Boehringer...
![](/fileadmin/_processed_/csm_Decoy_cell_cytology_f1d4d78e91.png)
Memo Therapeutics AG increases Series C financing to CHF45m
New investors Ysios Capital and Kurma Partners joined existing Series C round investors including Pureos Bioventures, Swisscanto, Vesalius...
![](/fileadmin/_processed_/csm_Fundus_of_patient_with_retinitis_pigmentosa__mid_stage_10790b28cb.jpg)
Three companies launch gene therapy alliance for eye diseases
Today, the companies officially announced the launch of the GEAR partnership (Evaluation of Adeno-Associated Virus Vector Gene Therapy for the...
![](/fileadmin/_processed_/csm_NALFD_model_7770420204.png)
DefiniGEN and Atelerix prevent freezing damage in cell models
The agreement between the British companies combines DefiniGEN’s iPSC hepatocytes (Opti-Heps) with Atelerix's hydrogel preservation technology, which...
![](/fileadmin/_processed_/csm_capsule_by_design_exvolvo-web_5315d0b612.jpg)
No more needles - Exvolvo arises with help of Verily and NLC Health
NLC Health Ventures launches a new early-stage drug delivery company. The venture builder from The Netherlands partners with Verily from which Exolvo...